Fuso Pharmaceutical Industries Ltd

Fuso Pharmaceutical Industries Ltd operates with a market capitalization of ¥18.87 billion and a price-to-book ratio of 0.57, indicating a discount to its book value. The company's liquidity position is characterized by a current ratio of 1.1 and cash and equivalents of ¥6.26 billion, but it also carries long-term debt of ¥21.29 billion, resulting in a debt-to-equity ratio of 0.64. The negative operating cash flow of ¥3.31 billion and free cash flow of ¥4.77 billion suggest ongoing liquidity challenges. Profitability metrics are weak, with a return on equity of -9.95% and return on assets of -4.02%, both significantly below the industry median for pharmaceutical firms. The company reported a net loss of ¥3.29 billion and an operating loss of ¥4.62 billion, indicating a need for operational restructuring or cost optimization to align with industry benchmarks. The company's revenue of ¥60.56 billion is derived from pharmaceuticals and real estate leasing. However, the financial data does not provide a breakdown of revenue by segment or geography, limiting the ability to assess concentration risk or geographic exposure. Looking ahead, the company's revenue outlook is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The negative operating and net income suggest a challenging growth trajectory, and the company may need to focus on improving margins or securing additional financing to support operations. The risk assessment highlights medium liquidity risk and low dilution risk. The key flag of negative net cash after subtracting total debt underscores the company's financial vulnerability. The absence of dilution risk is attributed to the low probability of new share issuance, but the company's financial position may necessitate capital raising in the near term. Recent events, including filings and transcripts, are not detailed in the provided data, so no specific recent developments can be cited. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.